Pacific Biomarkers, Inc. Names Sheri’ DuMond as Its New Director of Business Development

SEATTLE, WA--(Marketwire - January 31, 2011) - Pacific Biomarkers, Inc. (PBI) (OTCBB: PBMC), a provider of biomarker laboratory services to the pharmaceutical, biotechnology and diagnostics industries, has promoted Sheri’ DuMond to Director of Business Development following her role as Senior Associate Director of Business Development at PBI.

In her new position, Ms. DuMond will oversee the Business Development Team and lead PBI’s sales and marketing efforts to secure consistent revenue growth and optimize shareholder value. The Business Development Team is charged with promoting PBI’s capabilities among target customers and to leverage opportunities that represent accumulative financial strength and stability for all functions within the Company.

Prior to joining PBI, Sheri’s professional experience was rooted in the commercial side of the pharmaceutical industry, including positions at Novartis and Wyeth totaling 14 years. Sheri"s career path consistently led to positions of increasing responsibility in pharmaceutical sales; from a primary care sales representative, managed care/account manager, district sales manager, to national leadership team. Sheri’ received her Bachelor of Science degree in mass communications/journalism/public relations from Seattle University.

Ron Helm, PBI’s Chairman and Chief Executive Officer, said, “We are delighted to have Sheri’ in the important role of Director of Business Development. The skills and ingenuity that she demonstrated while serving as our Senior Associate Director of Business Development make her eminently suited for the job, and we look forward to benefiting from her talents as we seek to grow our revenue in 2011 and beyond.”

About Pacific Biomarkers, Inc. (PBI)
Established in 1989, PBI provides specialized central laboratory and contract research services to support pharmaceutical and diagnostic manufacturers conducting human clinical trial research. The Company provides expert services in the areas of cardiovascular disease, diabetes, osteoporosis, arthritis, and nutrition. The PBI laboratory is accredited by the College of American Pathologists, New York State, and the Lipid Standardization Program. PBI’s clients include many of the world’s largest pharmaceutical, biotech, and diagnostic companies. PBI also provides clinical biomarker services focusing on the emerging field of biomarker assay development and testing. Services include validating and performing ligand-binding assays for novel clinical biomarkers, immunogenicity testing, cell-based assay testing and multiplex testing.
PBI is headquartered in Seattle, Washington, and its common stock trades on the OTC Bulletin Board under the symbol “PBMC.” For more information about PBI, visit the company’s web site at www.pacbio.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This press release includes forward-looking statements including, but not limited to, the following: results of business development activities; future growth; and the viability and acceptance of the Company’s biomarker services. These forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to differ materially from those described in the forward-looking statements. These risks include, but are not limited to, the following: the Company’s ability to enter into contracts for its laboratory testing or biomarker services; client changes or early terminations of studies; variability in backlog; the success of marketing and business development efforts, and competitive factors; the Company’s ability to manage growth; and other risks and uncertainties set forth in periodic filings with the U.S. Securities and Exchange Commission (including Form 10-K for the year ended June 30, 2010).